Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...

With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...

(MENAFN- EIN Presswire) EINPresswire/ -- The RNA interference (RNAi) technology market has been experiencing remarkable growth recently, driven by advances in genetic research and increasing interest ...

The expansion will add about one-third more active manufacturing space to Alnylam's production facility in Norton, and it is ...

Alnylam Pharmaceuticals is to invest $250m to expand its facility in Massachusetts, US, to meet the growing demand for RNAi ...

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically ...

A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...

Reporting on ASH 2025, Dr Jamile Shammo highlights long-term follow-up data for established paroxysmal nocturnal hemoglobinuria (PNH) therapies as well as novel agents and combinations targeting the ...

With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...

Arrowhead Pharma doses first subjects in phase 1/2a study of ARO-MAPT to treat Alzheimer’s disease and other tauopathies: Pasadena, California Thursday, December 11, 2025, 12:00 ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

Alnylam Pharmaceuticals is expanding its Norton facility with a $250 million investment to enhance RNAi therapeutic ...